AstraZeneca says Klygefa recommended for EU approval
AstraZeneca said the EMA’s CHMP recommended Klygefa for EU approval.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BRIEF — Astrazeneca Says Klygefa Recommended For EU Approval To Treat Adults With Generalized Myasthenia Gravis
Sept 18 (Reuters) — AstraZeneca PLC: Astrazeneca: Klygefa (Gefurulimab) Recommended For Approval In Eu By Chmp For Treatment Of Adults With Generalised Myasthenia Gravis (Gmg) Source text:... Further company coverage: AZN.L (Reuters.Briefs@thomsonreuters.com;)
AstraZeneca says Klygefa recommended for EU approval in generalized myasthenia gravis
AstraZeneca said its Klygefa therapy was recommended for EU approval to treat adults with generalized myasthenia gravis.